Shilajit and Antidiabetic Medicines (Insulin, Metformin, Sulfonylureas)
Leila WehrhahnUpdated:Key points at a glance:
Shilajit is a resin traditionally used in Ayurveda that contains fulvic and humic acids. Preclinical data suggest a potential blood glucose-lowering effect. When used alongside insulin or sulfonylureas, this may increase the risk of low blood sugar. The potential risk appears lower with metformin, but close blood glucose monitoring is still recommended. Product quality can vary, and some samples have been found to contain heavy metals. Medical advice should be sought before use, start with a low dose, and be familiar with possible signs of low blood sugar.
Shilajit is a traditional Ayurvedic natural substance derived from humic-rich resins, and is increasingly used as a food supplement in Europe. It contains, among other components, fulvic and humic acids as well as dibenzo-α-pyrones. Preclinical data indicate potential blood sugar-lowering effects – this is where a possible risk of interaction with antidiabetic medicines arises. In particular, with insulin and sulfonylureas, an additional reduction in blood glucose associated with Shilajit use could contribute to hypoglycaemia. In addition, the quality and purity of Shilajit products can vary; some samples have been found to contain elevated levels of heavy metals. (1,2)
A general overview of the possible effects can be found in our article Shilajit effects.
Mechanism of interaction
Shilajit may influence glucose metabolism via several pathways. Animal studies have reported, among other things, improvements in insulin sensitivity and reductions in fasting blood glucose. In a rat model, Shilajit (100 mg/kg) enhanced the glucose-lowering effect of the sulfonylurea glibenclamide and, in combination with metformin, contributed to a more pronounced reduction in blood glucose – findings that suggest possible additive or synergistic effects. Extrapolating this principle to humans, a higher hypoglycaemia risk appears plausible when Shilajit is used alongside insulin or sulfonylureas. (3)
According to current guidelines, clinically relevant hypoglycaemia is mainly associated with therapy using insulin, sulfonylureas or meglitinides; the risk is higher when medicines are combined. (4)
Shilajit can enhance the effects of insulin and sulphonylureas, which increases the risk of hypoglycaemia.
Clinical evidence
Preclinical data
Several animal studies report blood sugar-lowering effects associated with Shilajit. In an alloxan-induced diabetes rat model, Shilajit reduced blood glucose in a dose-dependent manner and enhanced the effects of glibenclamide and metformin. (3)
In another model (NAFLD rats), two weeks of Shilajit administration was associated with lower fasting glucose and HOMA-IR (insulin resistance index), and modulation of inflammatory cytokines and adipokines. These findings are consistent with a potential improvement in insulin sensitivity. (5)
Human studies
Direct, high-quality human studies on blood sugar control with Shilajit as a single supplement are currently lacking. A randomised, placebo-controlled study of a combination formulation (chromium, Phyllanthus emblica and small amounts of Shilajit) showed indications of improvements including insulin sensitivity. Due to the combination formula and the very low Shilajit dose, the effect cannot be clearly attributed to Shilajit itself. (6)
Overall, the evidence supports the possibility of an additional blood sugar-lowering effect, but remains limited in humans. In practice, this suggests that caution is advisable when Shilajit is used together with antidiabetic medicines, particularly insulin and sulfonylureas.
Animal data show clear effects, but human data are limited. Nevertheless, clinical caution is advised.
Shilajit Capsules
Risk assessment
The potential interaction risk depends on the type of antidiabetic medicine and individual factors:
| Class of medicine | Mechanism | Main risk | Interaction severity | Recommendation |
|---|---|---|---|---|
| Insulin | Additive blood sugar-lowering effect | Hypoglycaemia | High | Only under medical supervision; frequent glucose monitoring; possible dose adjustment |
| Sulfonylureas (e.g. glibenclamide, glimepiride) | Stimulation of insulin secretion; potential enhancement by Shilajit | Hypoglycaemia | High | Avoid, or use only with medical supervision; education about hypoglycaemia; frequent SMBG/CGM |
| Metformin | Reduced hepatic glucose production, increased insulin sensitivity | Generally low hypoglycaemia risk as monotherapy | Low–moderate (higher in combination therapies) | Exercise caution, especially in combination with insulin/sulfonylureas; monitor values |
Guidelines emphasise that clinically relevant hypoglycaemia mainly concerns insulin and sulfonylurea therapies; combination therapies further increase this risk. (4)
Regardless of effects on glycaemia, product safety is an important consideration: reviews and analytical studies have reported inconsistent quality and, in some cases, elevated levels of lead, arsenic or mercury in Shilajit samples – an important safety argument against unsupervised self-medication. (1,2)
🧪 Shilajit Compatibility Check
Find out if there are any known risk factors that could contraindicate taking Shilajit.
Question 1 of 8
Practical recommendations
- Discuss with your doctor before starting: Explicitly mention any planned use of Shilajit if you are taking insulin, metformin or sulfonylureas.
- Baseline and monitoring:
- Begin with documented fasting and postprandial readings (e.g. a 7–10 day diary).
- After starting: for the first 2–4 weeks, measure fasting and postprandial values daily; with insulin/sulfonylureas, also measure before bedtime. CGM can be helpful.
- Be familiar with signs of hypoglycaemia: trembling, sweating, intense hunger, dizziness, confusion.
- Dosage and timing:
- If used at all, start only with the lowest dose recommended by the manufacturer. Avoid experimenting with your own dosing.
- A time gap of 2–3 hours from antidiabetic medicines may reduce peak overlap, but does not replace monitoring.
- With repeated readings <70 mg/dl (3.9 mmol/l): stop Shilajit and review antidiabetic dosing with your doctor.
- Product quality:
- Choose only purified, standardised products with a certificate of analysis (e.g. testing for heavy metals and microbiological quality). (1,2)
- Pregnant and breastfeeding women, and people with kidney disease or unexplained liver test abnormalities, should avoid Shilajit.
- Consider alternatives: If you are looking for “natural” support, a medically guided nutrition and exercise strategy is generally the safest option; certain, well-studied food supplements may be considered depending on the situation – always in consultation with a healthcare professional.
Further information on safety and interactions: Shilajit interactions and Shilajit side effects.
Conclusion
Shilajit has been investigated for potential blood sugar-lowering properties and may, in this context, influence the effects of insulin and sulfonylureas, with a correspondingly increased risk of hypoglycaemia. Human data are limited; however, preclinical findings and guideline-based reasoning support a cautious approach with close monitoring, particularly at the start of use and in combination regimens. Focus on products with documented quality, coordinate any use with your healthcare team and prioritise established measures such as nutrition, physical activity and guideline-based medication. (3,4)
Medical disclaimer
Important notice: This information does not replace professional medical advice. Always consult your doctor or pharmacist before using Shilajit together with antidiabetic medicines (insulin, metformin, sulfonylureas). Every individual may react differently to food supplements and medicines.